S

Sanofi

Global pharma company; vaccines and R&D

Biotechnologist Trainee - Career Conversion Program

Full-TimeUpdated on 10/23/2026Deadline 12/31/26
No salary listed
Entry
Singapore
In PersonOn-site at Sanofi Aventis Singapore, 5 Tuas South Street 2.
Biology & BiotechBioprocess & Biomanufacturing

About the job

Requirements
  • NITEC or a Diploma in an Engineering or Science discipline.
  • Be able to work in a twelve-hour rotating shift pattern consisting of day and night shifts.
  • Be able to operate and perform in cross-functional teams.
  • Have analytical and critical-thinking skills and the ability to problem-solve and navigate complexity and ambiguity.
  • Be able to work in fast-paced and dynamic conditions with tight timelines.
  • Have presentation and verbal communication skills and be able to adapt communication to various stakeholders.
  • Have technical writing skills.
Responsibilities
  • Execute routine current Good Manufacturing Practice manufacturing activities within the Upstream, Downstream, or Central Manufacturing Services (Media & Buffer, Logistics) teams, in accordance with process, quality, and safety standards.
  • Operate and monitor manufacturing equipment, digital systems, and automation systems during day-to-day production runs.
  • Perform general housekeeping of manufacturing areas.
  • Maintain regulatory and audit readiness through adherence to procedures and documentation standards.
  • Act as a key user of digital and automation applications and software supporting manufacturing systems, including enterprise resource planning, manufacturing execution systems, and process control systems.
  • Participate in continuous-improvement and optimization initiatives to enhance routine operational efficiency.
  • Support batch documentation, deviation reporting, and change-control activities as part of routine operations.
  • Perform day-to-day production activities within Upstream, Downstream, or Central Manufacturing Services, ensuring compliance with process, quality, and safety requirements.
  • Maintain and follow standard operating procedures, risk assessments, and training records for manufacturing equipment and systems.
  • Operate and troubleshoot digital and automation tools integrated into daily manufacturing processes.
  • Support routine batch production, in-process checks, and quality documentation in line with current Good Manufacturing Practice standards.
  • Identify and contribute to process-optimization opportunities within the assigned Upstream, Downstream, or Central Manufacturing Services area.
Desired Qualifications
  • Prior internships or industrial attachments in biopharmaceutical or biotechnology organizations are advantageous.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...